Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVX NASDAQ:LEGN NASDAQ:RYTM NASDAQ:VCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$82.28-4.2%$61.28$4.77▼$92.91$6.22B0.59695,985 shs777,788 shsLEGNLegend Biotech$34.34+1.4%$37.69$27.34▼$52.15$6.34B0.281.44 million shs1.12 million shsRYTMRhythm Pharmaceuticals$95.51-0.5%$93.99$45.90▼$106.52$6.34B2.23656,742 shs379,688 shsVCELVericel$33.23+5.8%$36.54$30.26▼$63.00$1.68B1.33531,091 shs1.13 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax+2.21%-4.59%+21.91%+1,317.00%+632.68%LEGNLegend Biotech+2.33%-2.14%-9.65%-2.36%-32.66%RYTMRhythm Pharmaceuticals-0.20%-3.75%-1.62%+54.96%+93.53%VCELVericel-2.36%-5.42%-13.40%-24.29%-31.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$82.28-4.2%$61.28$4.77▼$92.91$6.22B0.59695,985 shs777,788 shsLEGNLegend Biotech$34.34+1.4%$37.69$27.34▼$52.15$6.34B0.281.44 million shs1.12 million shsRYTMRhythm Pharmaceuticals$95.51-0.5%$93.99$45.90▼$106.52$6.34B2.23656,742 shs379,688 shsVCELVericel$33.23+5.8%$36.54$30.26▼$63.00$1.68B1.33531,091 shs1.13 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax+2.21%-4.59%+21.91%+1,317.00%+632.68%LEGNLegend Biotech+2.33%-2.14%-9.65%-2.36%-32.66%RYTMRhythm Pharmaceuticals-0.20%-3.75%-1.62%+54.96%+93.53%VCELVericel-2.36%-5.42%-13.40%-24.29%-31.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXAbivax 3.11Buy$99.4319.25% UpsideLEGNLegend Biotech 2.91Moderate Buy$74.22116.61% UpsideRYTMRhythm Pharmaceuticals 3.07Buy$101.576.10% UpsideVCELVericel 3.00Buy$60.4089.31% UpsideCurrent Analyst Ratings BreakdownLatest VCEL, RYTM, LEGN, and ABVX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025ABVXAbivaxMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$71.00 ➝ $101.009/9/2025ABVXAbivaxBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$112.008/27/2025LEGNLegend BiotechCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$66.008/25/2025LEGNLegend BiotechJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$77.00 ➝ $78.008/12/2025LEGNLegend BiotechRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$75.00 ➝ $77.008/12/2025LEGNLegend BiotechMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$81.00 ➝ $83.008/7/2025RYTMRhythm PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$80.00 ➝ $100.008/6/2025RYTMRhythm PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$119.00 ➝ $120.008/6/2025RYTMRhythm PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$130.00 ➝ $135.008/5/2025RYTMRhythm PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$100.00 ➝ $109.008/4/2025LEGNLegend BiotechCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXAbivaxN/AN/AN/AN/A$0.69 per shareN/ALEGNLegend Biotech$627.24M10.08N/AN/A$5.70 per share6.01RYTMRhythm Pharmaceuticals$156.29M40.69N/AN/A$0.35 per share273.53VCELVericel$237.22M6.79$0.31 per share102.98$5.92 per share5.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXAbivax-$190.71MN/A0.00N/AN/AN/AN/AN/AN/ALEGNLegend Biotech-$177.03M-$0.88N/AN/AN/A-40.83%-32.00%-20.07%11/11/2025 (Estimated)RYTMRhythm Pharmaceuticals-$260.60M-$3.01N/AN/AN/A-117.13%-1,831.43%-48.33%11/4/2025 (Estimated)VCELVericel$10.36M$0.12265.9872.51N/A2.85%2.47%1.69%11/6/2025 (Estimated)Latest VCEL, RYTM, LEGN, and ABVX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/8/2025Q2 2025ABVXAbivax-$0.90-$0.86+$0.04-$0.86$1.35 millionN/A8/11/2025Q2 2025LEGNLegend Biotech-$0.22-$0.34-$0.12-$0.34$237.49 million$255.06 million8/5/2025Q2 2025RYTMRhythm Pharmaceuticals-$0.66-$0.75-$0.09-$0.75$43.72 million$48.50 million7/31/2025Q2 2025VCELVericel-$0.04-$0.01+$0.03-$0.01$64.61 million$63.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABVXAbivaxN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXAbivax1.290.770.77LEGNLegend Biotech0.304.714.57RYTMRhythm PharmaceuticalsN/A2.792.64VCELVericelN/A4.974.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXAbivax47.91%LEGNLegend Biotech70.89%RYTMRhythm PharmaceuticalsN/AVCELVericelN/AInsider OwnershipCompanyInsider OwnershipABVXAbivaxN/ALEGNLegend Biotech0.02%RYTMRhythm Pharmaceuticals6.10%VCELVericel7.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXAbivax6175.57 millionN/ANot OptionableLEGNLegend Biotech2,609184.57 million184.53 millionOptionableRYTMRhythm Pharmaceuticals14066.42 million62.37 millionOptionableVCELVericel30050.46 million46.83 millionOptionableVCEL, RYTM, LEGN, and ABVX HeadlinesRecent News About These CompaniesVericel Corporation (NASDAQ:VCEL) Given Average Recommendation of "Buy" by BrokeragesSeptember 16 at 4:30 AM | marketbeat.comVericel (NASDAQ:VCEL) Shares Down 5.8% - Here's WhySeptember 12, 2025 | marketbeat.comHere’s Why Vericel Corp. (VCEL) Traded Down in Q2September 12, 2025 | msn.comJacobs Levy Equity Management Inc. Purchases Shares of 62,938 Vericel Corporation $VCELSeptember 12, 2025 | marketbeat.comIs the Options Market Predicting a Spike in Vericel Stock?September 11, 2025 | zacks.comVericel (NASDAQ:VCEL) Reaches New 52-Week Low - Should You Sell?September 10, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Sells 25,600 Shares of Vericel Corporation $VCELSeptember 10, 2025 | marketbeat.comRoyal Bank of Canada Boosts Stock Holdings in Vericel Corporation $VCELSeptember 8, 2025 | marketbeat.comTrexquant Investment LP Sells 57,615 Shares of Vericel Corporation $VCELSeptember 8, 2025 | marketbeat.comVericel’s Phase 3 Study on MACI: A Potential Game-Changer in Cartilage RepairSeptember 7, 2025 | tipranks.comVericel Corporation $VCEL Shares Bought by PDT Partners LLCSeptember 5, 2025 | marketbeat.comOMERS ADMINISTRATION Corp Invests $723,000 in Vericel Corporation $VCELSeptember 3, 2025 | marketbeat.com9,769 Shares in Vericel Corporation $VCEL Bought by Jump Financial LLCSeptember 3, 2025 | marketbeat.comVericel Corporation $VCEL Stock Position Decreased by Raymond James Financial Inc.August 31, 2025 | marketbeat.comNext Century Growth Investors LLC Boosts Stock Position in Vericel Corporation $VCELAugust 30, 2025 | marketbeat.comChamplain Investment Partners LLC Lowers Stock Position in Vericel Corporation $VCELAugust 30, 2025 | marketbeat.comVericel to Present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025August 28, 2025 | markets.businessinsider.comVericel to Present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025August 28, 2025 | globenewswire.comNuveen LLC Purchases New Position in Vericel Corporation $VCELAugust 28, 2025 | marketbeat.comWellington Management Group LLP Acquires 74,723 Shares of Vericel Corporation $VCELAugust 25, 2025 | marketbeat.comRussell Investments Group Ltd. Buys 31,635 Shares of Vericel Corporation $VCELAugust 25, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVCEL, RYTM, LEGN, and ABVX Company DescriptionsAbivax NASDAQ:ABVX$82.28 -3.59 (-4.18%) Closing price 04:00 PM EasternExtended Trading$82.87 +0.59 (+0.72%) As of 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Legend Biotech NASDAQ:LEGN$34.34 +0.46 (+1.36%) Closing price 04:00 PM EasternExtended Trading$34.34 0.00 (0.00%) As of 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Rhythm Pharmaceuticals NASDAQ:RYTM$95.51 -0.52 (-0.54%) Closing price 04:00 PM EasternExtended Trading$95.59 +0.08 (+0.08%) As of 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Vericel NASDAQ:VCEL$33.23 +1.81 (+5.76%) Closing price 04:00 PM EasternExtended Trading$33.23 0.00 (0.00%) As of 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
